These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 9009251)

  • 41. Role of deoxycytidine kinase in an in vitro model for AraC- and DAC-resistance: substrate-enzyme interactions with deoxycytidine, 1-beta-D-arabinofuranosylcytosine and 5-aza-2'-deoxycytidine.
    Stegmann AP; Honders MW; Kester MG; Landegent JE; Willemze R
    Leukemia; 1993 Jul; 7(7):1005-11. PubMed ID: 7686601
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Expression of multidrug resistance-associated protein (MRP), MDR1 and DNA topoisomerase II in human multidrug-resistant bladder cancer cell lines.
    Hasegawa S; Abe T; Naito S; Kotoh S; Kumazawa J; Hipfner DR; Deeley RG; Cole SP; Kuwano M
    Br J Cancer; 1995 May; 71(5):907-13. PubMed ID: 7734314
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Characterization and modulation of transitional cell carcinoma cell lines with acquired multidrug resistance.
    Yu DS; Chang SY; Ma CP
    Br J Urol; 1998 Feb; 81(2):234-40. PubMed ID: 9488065
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Overexpression of P-glycoprotein and alterations in topoisomerase II in P388 mouse leukemia cells selected in vivo for resistance to mitoxantrone.
    Kamath N; Grabowski D; Ford J; Kerrigan D; Pommier Y; Ganapathi R
    Biochem Pharmacol; 1992 Sep; 44(5):937-45. PubMed ID: 1356339
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Characterization of four drug-resistant P388 sublines: resistance/sensitivity in vivo, resistance-and proliferation-markers, immunogenicity.
    Fichtner I; Stein U; Hoffmann J; Winterfeld G; Pfeil D; Hentschel M
    Anticancer Res; 1994; 14(5A):1995-2003. PubMed ID: 7847840
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cytosine arabinoside (ara-C) resistance confers cross-resistance or collateral sensitivity to other classes of anti-leukemic drugs.
    Martin-Aragon S; Mukherjee SK; Taylor BJ; Ivy SP; Fu CH; Ardi VC; Avramis VI
    Anticancer Res; 2000; 20(1A):139-50. PubMed ID: 10769646
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evaluation of S9788 as a potential modulator of drug resistance against human tumour sublines expressing differing resistance mechanisms in vitro.
    Hill BT; van der Graaf WT; Hosking LK; de Vries EG; Mulder NH; Whelan RD
    Int J Cancer; 1993 Sep; 55(2):330-7. PubMed ID: 8103761
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Functional role of alternatively spliced deoxycytidine kinase in sensitivity to cytarabine of acute myeloid leukemic cells.
    Veuger MJ; Heemskerk MH; Honders MW; Willemze R; Barge RM
    Blood; 2002 Feb; 99(4):1373-80. PubMed ID: 11830489
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Modulation of intracellular metabolism of cytosine arabinoside in acute myeloid leukemia by granulocyte-macrophage colony-stimulating factor.
    Reuter C; Auf der Landwehr U; Schleyer E; Zühlsdorf M; Ameling C; Rolf C; Wörmann B; Büchner T; Hiddemann W
    Leukemia; 1994 Feb; 8(2):217-25. PubMed ID: 8309245
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cyclosporin A, verapamil and S9788 reverse doxorubicin resistance in a human medullary thyroid carcinoma cell line.
    Massart C; Gibassier J; Raoul M; Pourquier P; Leclech G; Robert J; Lucas C
    Anticancer Drugs; 1995 Feb; 6(1):135-46. PubMed ID: 7756676
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Reactive oxygen species-specific mechanisms of drug resistance in paraquat-resistant acute myelogenous leukemia sublines.
    Choi CH; Kim HS; Kweon OS; Lee TB; You HJ; Rha HS; Jeong JH; Lim DY; Min YD; Kim MS; Chung MH
    Mol Cells; 2000 Feb; 10(1):38-46. PubMed ID: 10774745
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Sensitivity of K562 human chronic myelogenous leukemia blast cells transfected with a human multidrug resistance cDNA to cytotoxic drugs and differentiating agents.
    Hait WN; Choudhury S; Srimatkandada S; Murren JR
    J Clin Invest; 1993 May; 91(5):2207-15. PubMed ID: 8098047
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Decreased mutation rate for cellular resistance to doxorubicin and suppression of mdr1 gene activation by the cyclosporin PSC 833.
    Beketic-Oreskovic L; Durán GE; Chen KG; Dumontet C; Sikic BI
    J Natl Cancer Inst; 1995 Nov; 87(21):1593-602. PubMed ID: 7563202
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Development of vincristine resistance and increased sensitivity to cyclosporin A and verapamil in the human U-937 lymphoma cell line without overexpression of the 170-kDa P-glycoprotein.
    Botling J; Liminga G; Larsson R; Nygren P; Nilsson K
    Int J Cancer; 1994 Jul; 58(2):269-74. PubMed ID: 7913083
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Lack of cross-resistance between cytosine arabinoside and a new halogenated nucleoside analogue, 2-bromo-2'-deoxyadenosine in human acute myeloid leukaemia cells.
    Pemble LB; Lihou MG; Blakley RL; Jamieson GP; Smith PJ
    Cancer Chemother Pharmacol; 1987; 20(2):155-61. PubMed ID: 3499252
    [TBL] [Abstract][Full Text] [Related]  

  • 56. In vivo development of cytosine arabinoside resistance in the BN acute myelocytic leukemia.
    Hagenbeek A; Martens AC; Colly LP
    Semin Oncol; 1987 Jun; 14(2 Suppl 1):202-6. PubMed ID: 3473677
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Anticancer drug-mediated induction of multidrug resistance-associated genes and protein kinase C isozymes in the T-lymphoblastoid cell line CCRF-CEM and in blasts from patients with acute lymphoblastic leukemias.
    Beck JF; Brügger D; Brischwein K; Liu C; Bader P; Niethammer D; Gekeler V
    Jpn J Cancer Res; 2001 Aug; 92(8):896-903. PubMed ID: 11509123
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacological and biological evidence for differing mechanisms of doxorubicin resistance in two human tumor cell lines.
    Slovak ML; Hoeltge GA; Dalton WS; Trent JM
    Cancer Res; 1988 May; 48(10):2793-7. PubMed ID: 2896069
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Characterization of resistance to cytosine arabinoside (Ara-C) in NALM-6 human B leukemia cells.
    Kanno S; Hiura T; Ohtake T; Koiwai K; Suzuki H; Ujibe M; Ishikawa M
    Clin Chim Acta; 2007 Feb; 377(1-2):144-9. PubMed ID: 17097625
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evaluation of multiple drug resistance in human bladder cancer cell lines.
    Shinohara N; Liebert M; Wedemeyer G; Chang JH; Grossman HB
    J Urol; 1993 Aug; 150(2 Pt 1):505-9. PubMed ID: 8100862
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.